Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Survival and years of life lost in different age cohorts of patients with multiple myelomaHeinz Ludwig, Vanessa Bolejack, John Crowley, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
British Journal of Haematology|February 18, 2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyMeletios A Dimopoulos, A Keith Stewart, Tamás Masszi, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
Leukemia|July 3, 2013
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptomsBrian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
The American Journal of Pathology|October 7, 2004
Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosisMargarida Lima, Julia Almeida, Andrés García Montero, et al.
The Lancet. Oncology|February 5, 2021
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working GroupEvangelos Terpos, Elena Zamagni, Suzanne Lentzsch, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Pageof 13